• Boston Scientific to sell BTG Specialty Pharmaceuticals business for $800m pharmaceutical-technology
    December 03, 2020
    Boston Scientific has signed a definitive agreement with SERB’s affiliates, Stark International and SERB SAS, to divest its BTG Specialty Pharmaceuticals business for $800m in cash.
  • Recipharm, SERB Enter Agreement contractpharma
    June 19, 2018
    Recipharm has signed and closed an agreement with SERB SA (“SERB”) on a divestment of its rights to its potassium iodide product ThyroSafe® except for the US territory. 
PharmaSources Customer Service